JPM 2022: Abiomed, Penumbra, Renalityx

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.

J.P. Morgan Daily Notebook 2022 Day 4
• Source: Alamy

Results from the VENUS HF first-in-human early feasibility study shows Abiomed’s preCARDIA occlusion device promotes decongestion in patients with acutely decompensated heart failure, the company announced on 12 January.

The preCARDIA system is designed to reduce pressure on the heart and lungs by intermittently occluding the superior vena cava,...

More from Policy & Regulation

More from Medtech Insight